Conversely, the success of targeted antisense oligonucleotide (ASO) therapy in superoxide dismutase 1 (SOD-1) SOD1-ALS [56] provides a powerful analogue for similar trials in FTD, validating that taking a precision medicine approach for genetic FTD could have similar success. Here, SOD1 is linked to frontotemporal dementia.